Last reviewed · How we verify

CCK (Kinevac) — Competitive Intelligence Brief

CCK (Kinevac) (CCK (Kinevac)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CCK receptor agonist. Area: Gastroenterology / Diagnostic.

marketed CCK receptor agonist CCK-A receptor Gastroenterology / Diagnostic Small molecule Live · refreshed every 30 min

Target snapshot

CCK (Kinevac) (CCK (Kinevac)) — GlaxoSmithKline. CCK (cholecystokinin) is a synthetic peptide hormone that binds to CCK receptors to stimulate gallbladder contraction and pancreatic secretion.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CCK (Kinevac) TARGET CCK (Kinevac) GlaxoSmithKline marketed CCK receptor agonist CCK-A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CCK receptor agonist class)

  1. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CCK (Kinevac) — Competitive Intelligence Brief. https://druglandscape.com/ci/cck-kinevac. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing